Allievex Corporation

Spruce Biosciences is securing rights to a shelved BioMarin rare disease candidate in a bid to revive its pipeline – but it will need additional funding to get that program to market. On 15 April, the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

Patient advocates, sponsors and clinical experts are protesting what they view as generally unworkable recommendations from the US Food and Drug Administration on development approaches and clinical t